In addition to the shares sold in the underwritten public offering, Lexicon granted the underwriters a 30-day option to purchase up to an additional 4,800,000 shares of common stock at the public ...

Lexicon Pharmaceuticals shares were 21% lower, at $1.14, after the company priced its underwritten public offering of 32 million shares at $1.30 a share. All of the shares are being offered by Lexicon ...

As of Friday, January 30, Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 16.32%, which has investors ...

THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May 13 ...

Investing.com -- Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) stock fell 14.9% Friday after the company announced the pricing of ...

Lexicon Pharma (LXRX) prices 32M-share offering at $1.30 and $41M+ private placement to fund R&D and working capital—get the key details now.

Jefferies and Piper Sandler are acting as joint book-running managers for the proposed offering.

Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...

THE WOODLANDS, Texas, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today the completion of the sale of Lexicon’s rights, title and interest in XERMELO ® ...